Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China

May 14 (Reuters) - Zai Lab Ltd  9688.HK :
    * ZAI LAB ANNOUNCES ACCEPTANCE OF SUPPLEMENTAL BIOLOGICS
LICENSE
APPLICATION WITH PRIORITY REVIEW FOR EFGARTIGIMOD ALFA INJECTION
(SUBCUTANEOUS INJECTION) IN CHRONIC INFLAMMATORY DEMYELINATING
POLYNEUROPATHY (CIDP) IN CHINA
    * ZAI LAB LTD -SBLA SUBMISSION BASED ON POSITIVE RESULTS
FROM
ADHERE TRIAL

Source text for Eikon:  ID:nBw1PgjfPa 
Further company coverage:  9688.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Zai Lab

See all news